Table 1 Patient, disease, and treatment characteristics
Characteristics | N (%) |
|---|---|
Age, years | |
Median (range) | 58 (41–82) |
Gender | |
Male | 118 (95.9%) |
Female | 5 (4.1%) |
Tumor site | |
Pyriform sinus | 106 (86.2%) |
Posterior pharyngeal wall | 9 (7.3%) |
Postcricoid area | 8 (6.5%) |
TNM stage | |
II | 7 (5.7%) |
III | 25 (20.3%) |
IVa | 83 (67.5%) |
IVb | 8 (6.5%) |
Clincal T stage | |
T1 | 7 (5.7%) |
T2 | 19 (15.4%) |
T3 | 29 (23.6%) |
T4 | 28 (22.8%) |
Pathological T stage | |
T1 | 5 (4.1%) |
T2 | 12 (9.8%) |
T3 | 10 (8.1%) |
T4 | 13 (10.6%) |
Clincal N stage | |
N0 | 12 (9.8%) |
N1 | 16 (13.0%) |
N2a | 2 (1.6%) |
N2b | 25 (20.3%) |
N2c | 19 (15.4%) |
N3 | 3 (2.4%) |
Pathological N stage | |
N0 | 6 (4.9%) |
N1 | 7 (5.7%) |
N2a | 1 (0.8%) |
N2b | 26 (21.1%) |
N2c | 5 (4.1%) |
N3 | 1 (0.8%) |
Surgery | |
Total laryngopharyngectomy and neck dissection | 20 (16.3%) |
Partial laryngopharyngectomy and neck dissection | 20 (16.3%) |
Isolated neck dissection | 6 (4.9%) |
Node dissection | |
Ipsilateral | 35 (28.5%) |
Bilateral | 11 (8.9%) |
Intensity-modulated radiotherapy | |
Postoperative | 40 (32.5%) |
Definitive | 77 (62.6%) |
Chemotherapy | |
Induction | 54 (43.9%) |
Concurrent | 28 (22.8%) |